Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO
convened an Expert Panel and conducted a systematic review of the medical literature for …

The significant physical and emotional effects of chemotherapy-induced nausea and
vomiting (CINV) are experienced by cancer patients. Severe symptoms decrease the …

PURPOSE To update the guideline to include new anticancer agents, antiemetics, and
antiemetic regimens and to provide recommendations on the use of dexamethasone as a …

Abstract High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is
used to treat a range of adult and childhood cancers. Although HDMTX is safely …

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant
deterioration in quality of life and is perceived by patients as a major adverse effect of the …

Summary Growth differentiation factor 15 (GDF15) is a cytokine that reduces food intake
through activation of hindbrain GFRAL-RET receptors and has become a keen target of …

Background Cannabis has a long history of medicinal use. Cannabis‐based medications
(cannabinoids) are based on its active element, delta‐9‐tetrahydrocannabinol (THC), and …

Purpose To update a key recommendation of the American Society of Clinical Oncology
antiemetic guideline. This update addresses the use of the oral combination of netupitant (a …

Patients with cancer should appropriately receive antiemetic therapies against
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …

Background While guidelines for preventing chemotherapy-induced nausea and vomiting
(CINV) are widely available, clinical uptake of guidelines remains low. Our objective was to …